In a cross-sectional study conducted in 433 patients with psychotic disorders in the Netherlands we found a prevalence of metabolic syndrome of 33%. This was lower than in studies conducted in patients with psychotic disorders in the US, but at the high end compared to other European countries and considerably higher than in the general population in the Netherlands. Patients with metabolic syndrome were older, had a longer duration of disease, and received more often clozapine and less often olanzapine than patients without metabolic syndrome.
Introduction
Patients with chronic psychotic disorders have an elevated risk for developing cardiovascular and metabolic diseases. 1 The metabolic syndrome is a measure for the clustering of metabolic and cardiovascular risk factors and is frequently used in patients with psychotic disorders. 2, 3 So far, no study has been conducted to describe the prevalence of the metabolic syndrome in patients with psychotic disorders in the Netherlands. This study aimed to estimate the prevalence of metabolic syndrome and to compare characteristics of patients with metabolic syndrome to those without.
Methods
This cross-sectional analysis of patients with psychotic disorders participating in a disease 
Results
In total, 433 patients were included in the analysis. This was 55% of all patients (n=785) treated in the department of psychotic disorders during the inclusion period. Age and sex distribution were similar between included patients and total population. Of the total and female patients (10%, n=16). Patients with metabolic syndrome were significantly older, had a longer duration of disease, and significantly more frequently a positive family history of diabetes. (Table 1) The diagnosis schizophrenia and schizoaffective disorder were more prevalent in patients with metabolic syndrome than in patients without metabolic syndrome.
Most patients with other psychotic disorders did not have metabolic syndrome.
Seventy-six percent (n=331) of all patients received one antipsychotic drug; Patients with metabolic syndrome received more often clozapine than olanzapine, while patients without metabolic syndrome received more often olanzapine than clozapine. Furthermore, patients with metabolic syndrome received more often a combination of antipsychotic drugs and less often no antipsychotic drug than those without metabolic syndrome.
Discussion
In our study 32% of patients with psychotic disorders fulfilled the criteria for metabolic syndrome. This prevalence was lower than reported from studies conducted in patients with psychotic disorders in North America (US: 41%, 2 Canada: 45% 7 ), and at the high end compared to studies conducted in Europe (Spain: 25%, 3 , Belgium: 28%, 1 Sweden: 35% 8 ). It was considerable higher than in the general Dutch population: in slightly older cohorts it ranged from 10% to 12% for females and from 16% to 19% for males. 9 The most concerning finding was the high prevalence of abdominal obesity in female patients. Even females without metabolic syndrome fulfilled on average the waist circumference criterion. Similar findings have been described previously and resulted in a higher prevalence of metabolic syndrome in females compared to males. 2, 3 We found an equal prevalence of the metabolic syndrome in males and females, however compared to the general population the prevalence of metabolic syndrome in female psychotic patients was more elevated than in male patients. Similar to van Winkel et al 10 we found the highest prevalence of metabolic syndrome in patients with schizoaffective disorders followed by those with schizophrenia. Patients with other psychotic disorders had the lowest prevalence of metabolic syndrome, but those also had the shortest average duration of disease. (data not shown)
Clozapine and olanzapine have a similar high risk of causing diabetes, dyslipidemia and overweight. 11 In our study, patients with metabolic syndrome received more often clozapine than olanzapine, while those without metabolic syndrome received more often olanzapine than clozapine. These differences might be due to the different switching strategies for these drugs. Patients with metabolic side effects may have been more easily switched to other drugs from olanzapine than from clozapine, because clozapine was mostly prescribed for therapy resistant patients while olanzapine was a first choice drug. This is supported by the younger age and shorter duration of disease of the patients receiving olanzapine compared to those receiving clozapine. (data not shown) The prevalence of metabolic syndrome was also elevated in patients receiving more than one antipsychotic drug. Most probably this is caused by other factors related to the use of combinations than the combination itself. Correl et al 12 demonstrated that antipsychotic polypharmacy was related with a higher prevalence of metabolic syndrome, however not after correcting for age, diagnosis, treatment and BMI.
This study was limited by the use of HbA1c as a surrogate parameter for fasting glucose.
However when only including patients with fasting glucose measures in the analysis, we found equal or similar prevalences of the metabolic syndrome. In conclusion, our study described that the prevalence of metabolic syndrome amongst patients with psychotic disorders in the Netherlands is high and screening and treatment are strongly required.
